spierschade na fysieke inspanning muscle damage muscle function muscle soreness
Conditions
Interventions
Volunteers will consume either a whey protein supplement (60 g protein/d) or an
isocaloric placebo supplement (maltodextrin), additional to their habitual
diet, during 9 days. A dose of 20 g protein
Sponsors
NIZO food research B.V.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Male * Age *18 and *35 years. * BMI *18.5 and *27.5 kg/m2 * Healthy as assessed by the NIZO lifestyle and health questionnaire. * Recreationally active, defined as performing physical activities on a recreational basis for a maximal duration of 5 hours per week. * Veins suitable for cannulation (blood sampling) * Having given written informed consent
Exclusion criteria
Exclusion criteria: * Having a history of medical or surgical events that may significantly affect the study outcome, to be decided by the principal investigator * Participating in resistance exercise or exercise with a major eccentric component (e.g. (trail) running, football, volleyball, basketball, track and field) in the last 6 months. * Regular use of the following medication: corticosteroids, antihistamines, NSAID * Smoking * Regular use of protein supplements * Mental status that is incompatible with the proper conduct of the study * A self-reported reported lactose intolerance, allergy or sensitivity to dairy ingredients * Evidence of current excessive alcohol consumption (>21 units/week) or drug (ab)use, and not willing/able to stop this during the study. * Reported slimming or medically prescribed diet * Participation in any clinical trial including blood sampling and/or administration of substances up to 30 days before Day 01 of this study * Recent blood donation (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in muscle strength of the quadriceps muscles (isokinetic Maximal Voluntary Contraction (MVC)) up to 3 days after eccentric exercise, compared to pre-exercise strength. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Isometric MVC * Jump height assessed by vertical countermovement jump. * Thigh circumference. * Delayed onset muscle soreness (DOMS) assessed by VAS (100 mm) * Muscle soreness assessed by a 7 point Likert-scale for retrospective pain. * Muscle tenderness assessed by a manual muscle myometer. * Rated perceived exertion (RPE), assessed by the BORG scale. * Plasma creatine kinase (CK) concentrations * Plasma intestinal fatty acid binding protein (I-FABP) concentrations * Circulating neutrophils and monocytes (white blood cell count) in whole blood * Plasma concentrations of IL-6, MCP-1, IL-1ra, IL-8 and IL-10 * Plasma concentrations of NGF | — |
Countries
Netherlands
Outcome results
None listed